XML 21 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue Recognition
9 Months Ended
Sep. 30, 2017
Revenue Recognition [Abstract]  
Revenue Recognition

6.

Revenue Recognition

Concentration of Significant Customers

Six direct customers comprised 61% of our revenue recognized for the nine months ended September 30, 2017.   Four direct customers accounted for 78% of total outstanding accounts receivable (excluding receivables from the Biomedical Advanced Research Development Authority, a division of the U.S. Department of Health and Human Services (“BARDA”)) as of September 30, 2017.

Three distributors and two direct customers comprised 80% of our revenue recognized for the nine months ended September 30, 2016.  Two distributors and one direct customer accounted for 28% of total outstanding accounts receivable as of September 30, 2016.

Product revenues, classified by geographic location, are as follows (in thousands):

 

 

 

Three months ended

 

 

Nine months ended

 

 

 

September 30, 2017

 

 

September 30, 2016

 

 

September 30, 2017

 

 

September 30, 2016

 

 

 

Product

Revenues

 

 

% of

Total

 

 

Product

Revenues

 

 

% of

Total

 

 

Product

Revenues

 

 

% of

Total

 

 

Product

Revenues

 

 

% of

Total

 

Americas

 

$

112

 

 

 

24

%

 

$

79

 

 

 

11

%

 

$

315

 

 

 

15

%

 

$

670

 

 

 

21

%

Japan

 

 

279

 

 

 

60

%

 

 

575

 

 

 

79

%

 

 

1,434

 

 

 

71

%

 

 

2,232

 

 

 

70

%

EMEA

 

 

18

 

 

 

4

%

 

 

76

 

 

 

10

%

 

 

204

 

 

 

10

%

 

 

281

 

 

 

9

%

Asia Pacific

 

 

58

 

 

 

12

%

 

 

1

 

 

 

0

%

 

 

74

 

 

 

4

%

 

 

7

 

 

 

0

%

Total product revenues

 

$

467

 

 

 

100

%

 

$

731

 

 

 

100

%

 

$

2,027

 

 

 

100

%

 

$

3,190

 

 

 

100

%

 

Research and Development

We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contracts and other within development revenues.  Government contract revenue is recorded at the gross amount of the reimbursement.  The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations.   We recognized $1.3 million and $2.9 million in BARDA revenue for the three and nine months ended September 30, 2017, as compared to $1.9 million and $5.2 million for the three and nine months ended September 30, 2016.